1. Home
  2. NCRA vs CING Comparison

NCRA vs CING Comparison

Compare NCRA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$1.22

Market Cap

13.2M

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.41

Market Cap

26.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
CING
Founded
2002
2012
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
26.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NCRA
CING
Price
$1.22
$4.41
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.33
AVG Volume (30 Days)
45.2K
119.5K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$3.20
52 Week High
$2.40
$6.01

Technical Indicators

Market Signals
Indicator
NCRA
CING
Relative Strength Index (RSI) 56.94 71.13
Support Level $0.83 $3.75
Resistance Level $0.95 $4.02
Average True Range (ATR) 0.10 0.21
MACD 0.04 0.07
Stochastic Oscillator 85.11 96.30

Price Performance

Historical Comparison
NCRA
CING

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: